Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the Drug Registration Certificate for Arolol Hydrochloride Tablets (10mg) from the National Medical Products Administration, which will enhance the company's product line and market competitiveness [1] Group 1 - The drug is indicated for primary hypertension (mild to moderate), angina pectoris, tachyarrhythmia, and essential tremor [1] - The approval of the Drug Registration Certificate will further enrich the company's product offerings [1] - This development is expected to improve the company's market competitiveness [1]

关于盐酸阿罗洛尔片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局（以下简称"国家药监局"）颁发的盐酸阿罗洛 尔片（规格：10mg）（以下简称"该药品"）《药品注册证书》（证 书编号：2025S02717），批准该药品生产。现将相关情况公告如下： | 药品名称 | 药品通用名称：盐酸阿罗洛尔片 | | --- | --- | | | 英文名/拉丁名：Arotinolol Hydrochloride Tablets | | 剂型 | 片剂 | | 注册分类 | 化学药品4类 | | 规格 | 10mg | | 药品批准文号 | 国药准字H20255323 | | 药品注册标准编号 | YBH21362025 | | 处方药/非处方药 | 处方药 | | 申请事项 | 药品注册（境内生产） | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规 定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。质量标准 ...

福元医药公告，近日收到国家药品监督管理局颁发的盐酸阿罗洛尔片（规格：10mg）《药品注册证 书》（证书编号：2025S02717），批准该药品生产。盐酸阿罗洛尔片用于原发性高血压、心绞痛、心 动过速性心律失常、原发性震颤。公司于2024年3月26日获得申报受理通知书，并于近日获得国家药监 局批准。根据国家相关政策规定，本次获得《药品注册证书》，视同通过一致性评价。截至本公告日， 公司针对该药品累计研发投入为人民币397.07万元（未经审计）。 ...

福元医药(601089)今日下跌9.66%，全天换手率6.18%，成交额7.29亿元，振幅7.86%。龙虎榜数据显 示，营业部席位合计净卖出4222.63万元。 8月19日公司发布的半年报数据显示，上半年公司共实现营业收入16.34亿元，同比下降1.30%，实现净 利润2.68亿元，同比下降7.83%。（数据宝） 福元医药9月5日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 方正证券股份有限公司长沙芙蓉中路证券营业部 | 2361.59 | | | 买二 | 招商证券股份有限公司深圳红岭路证券营业部 | 2079.95 | | | 买三 | 广发证券股份有限公司上海浦东新区东方路证券营业部 | 1817.12 | | | 买四 | 招商证券股份有限公司长沙芙蓉中路证券营业部 | 994.93 | | | 买五 | 中国银河证券股份有限公司台州东海大道证券营业部 | 954.76 | | | 卖一 | 东方证券股份有限公司无锡新生路证券营业部 | | 2706.51 | | ...

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Amlodipine Benazepril Capsules, which will enhance the company's product line and market competitiveness [1][4]. Drug Registration Certificate Details - The drug is approved for production by the National Medical Products Administration, with the registration certificate number 2025S02582 [1]. - Amlodipine Benazepril Capsules are indicated for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone, or for those requiring a switch from separate Amlodipine and Benazepril tablets [1]. R&D Investment - The company has invested a total of RMB 8.1616 million (approximately 1.1 million USD) in the research and development of this drug [2]. Market Situation of Similar Drugs - According to data from Minai Network, the sales revenue of Amlodipine Benazepril oral formulations in China is approximately RMB 1.12 billion (about 160 million USD) for 2024 [3]. - The sales distribution includes RMB 727 million (about 102 million USD) from urban public hospitals and county-level public hospitals, RMB 167 million (about 24 million USD) from urban community centers and township health clinics, and RMB 226 million (about 32 million USD) from urban pharmacies and online pharmacies [3]. Impact on the Company - The approval of the drug will enrich the company's product line and enhance its market competitiveness [4].

创新药概念股盘中走低，舒泰神、前沿生物跌超10%，福元医药跌停，百花医药、亚太药业、万邦德、 百利天恒、睿智医药等多股跌超5%。 ...

每经AI快讯，9月5日，A股早盘创新药概念震荡调整，福元医药跌停，前沿生物跌超10%，百花医药、 济民健康、舒泰神、百利天恒等多股跌超5%。 （文章来源：每日经济新闻） ...

Group 1 - The innovative drug concept sector experienced fluctuations in early trading, with several companies facing significant declines [1] - Fuyuan Pharmaceutical hit the daily limit down, indicating a strong negative market reaction [1] - Frontier Biotech dropped over 10%, reflecting investor concerns in the sector [1] Group 2 - Other companies such as Baihua Pharmaceutical, Jimin Health, Shutaishen, Bailitianheng, and Chengdu Xian Dao also saw declines exceeding 5% [1]

Core Viewpoint - Fuyuan Pharmaceutical has received approval from the National Medical Products Administration for the production of Amlodipine Benazepril Capsules, marking a significant milestone for the company in expanding its product offerings [1] Group 1 - The approved drug contains Amlodipine (5mg) and Benazepril (10mg) per capsule, indicating a combination therapy for hypertension [1] - The drug registration certificate number is 2025S02582, which formalizes the approval process [1]

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]